Relay Therapeutics (RLAY) Projected to Announce Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $0.96 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $5.58 million. On average, analysts expect Relay Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relay Therapeutics Price Performance

Shares of NASDAQ:RLAY opened at $18.37 on Thursday. Relay Therapeutics has a 12 month low of $3.03 and a 12 month high of $20.79. The firm has a market capitalization of $3.52 billion, a P/E ratio of -11.70 and a beta of 1.67. The company’s fifty day moving average price is $16.94 and its 200 day moving average price is $12.95.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Citizens Jmp raised their price objective on Relay Therapeutics from $19.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 20th. Wells Fargo & Company boosted their target price on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Zacks Research cut Relay Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Wall Street Zen upgraded Relay Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Canaccord Genuity Group started coverage on Relay Therapeutics in a research report on Thursday, July 16th. They set a “buy” rating and a $29.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Relay Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $24.92.

Insider Buying and Selling

In other news, insider Peter Rahmer sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the transaction, the insider owned 225,857 shares of the company’s stock, valued at approximately $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Thomas Catinazzo sold 187,163 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11. Following the sale, the chief financial officer owned 177,461 shares of the company’s stock, valued at $3,011,513.17. This trade represents a 51.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 422,912 shares of company stock valued at $7,378,537. Company insiders own 5.04% of the company’s stock.

Hedge Funds Weigh In On Relay Therapeutics

A number of large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in Relay Therapeutics by 11.9% in the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after purchasing an additional 38,812 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Relay Therapeutics by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after purchasing an additional 5,238 shares during the period. Millennium Management LLC increased its position in Relay Therapeutics by 14.6% during the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Relay Therapeutics during the 1st quarter worth approximately $53,000. Finally, Woodline Partners LP raised its stake in shares of Relay Therapeutics by 448.4% during the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after buying an additional 1,241,657 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.